U.S.-based Huya Bioscience Signs Drug Development Pact With China's Guangzhou Institutes Of Biomedicine
This article was originally published in PharmAsia News
Executive Summary
BEIJING - Huya Bioscience International has signed a partnership agreement with the Guangzhou Institutes of Biomedicine and Health on the joint development of innovative compounds that could provide a bridge between GIBH scientists and the global market, according to Huya's senior leadership